Combinational immunotherapy based on immune checkpoints inhibitors in small cell lung cancer: is this the beginning to reverse the refractory situation?

Small cell lung cancer (SCLC), a particular neuroendocrine tumor, occupies 13% of lung cancers, with the highest mortality among cancers. Immune checkpoints inhibitors (ICIs) based on programmed cell death protein-1 (PD-1)/programmed cell death one ligand (PD-L1) inhibitors and cytotoxic T-lymphocyt...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Haoyue, He, Yayi, Chen, Peixin, Wang, Lei, Li, Wei, Chen, Bin, Liu, Yu, Wang, Hao, Zhao, Sha, Zhou, Caicun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656422/
https://www.ncbi.nlm.nih.gov/pubmed/33209440
http://dx.doi.org/10.21037/jtd-20-1689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656422/
https://www.ncbi.nlm.nih.gov/pubmed/33209440
http://dx.doi.org/10.21037/jtd-20-1689

Ejemplares similares